Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 4/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774211 | 1.00 | MAP4K4 (0.45) | MAP4K4HRH4HRH3JAK1JAK2 | |
| SCHEMBL17748984 | 0.92 | OPRD1 (0.39) | MAP4K4HRH4HRH3JAK1OPRD1 | |
| SCHEMBL1775092 | 0.90 | P4HTM (0.35) | MAP4K4HRH4HRH3JAK1JAK3 | |
| SCHEMBL1774527 | 0.84 | HRH4 (0.58) | MAP4K4HRH4HRH3JAK2JAK3 | |
| SCHEMBL1775585 | 0.84 | HRH4 (0.58) | MAP4K4HRH4HRH3JAK2JAK3 | |
| SCHEMBL6023882 | 0.81 | LMNA (0.56) | MAP4K4HRH4HRH3 | |
| SCHEMBL1775506 | 0.81 | LMNA (0.56) | MAP4K4HRH4HRH3 | |
| SCHEMBL5076739 | 0.81 | LMNA (0.56) | MAP4K4HRH4HRH3 | |
| SCHEMBL16854338 | 0.76 | GPR119 (0.45) | HRH4HRH3JAK1JAK2JAK3 | |
| SCHEMBL21858200 | 0.76 | OPRM1 (0.39) | MAP4K4HRH4HRH3MCHR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | MAP4K4 3321/4885HRH4 184/4885HRH3 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.